Biopharmaceutical Process Scale-Up Risk Analyst

Bioprocess engineers at CDMOs or in-house manufacturing teams face the transition from lab-scale (2–50 L) to commercial-scale (2,000–20,000 L) bioreactor production. They use this agent to systematically identify scale-dependent failure modes before committing capital to GMP campaigns.